Cost of colorectal cancer screening in two tribal health organizations in Alaska
- PMID: 40699475
- PMCID: PMC12362863
- DOI: 10.1007/s10552-025-02036-w
Cost of colorectal cancer screening in two tribal health organizations in Alaska
Abstract
Purpose: We conducted a comprehensive assessment of the resources required to undergo colorectal cancer (CRC) screening in two Alaska Native tribal health organizations.
Methods: We evaluated the cost of CRC screening at Maniilaq Association and Bristol Bay Area Health Corporation, and the communities they serve. We developed a tailored data collection tool to gather data from health clinics. We calculated the cost of screening tests and patient costs. We also conducted interviews with clinic representatives to identify contextual factors that can affect cost estimates.
Results: The cost of fecal immunochemical tests and fecal occult blood tests ranged from $53 to $76. The cost of the colonoscopy procedure ranged from $2,600 to $4,066. Travel costs, including per diem, ranged from $1,561 to $1,740. The cost of missed work was estimated to be $1,008 for patients and medical escorts for both communities. The total cost of receiving a colonoscopy, including procedural costs, travel costs, and the cost of missed work, ranged from $5,348 to $6,635.
Conclusion: We found the cost of the screening tests, travel costs and the cost of missed work to undergo CRC screening were higher in Alaska than national averages. Program planning could benefit from accounting for the costs and additional resources needed in Alaska due to the geography of the state and the location of providers and facilities.
Keywords: Alaska public health; Cancer screening; Colorectal cancer; Patient navigation; Program cost.
© 2025. This is a U.S. Government work and not under copyright protection in the US; foreign copyright protection may apply.
Conflict of interest statement
Declarations. Conflict of interest: The authors declare no competing interests. Ethical approval: RTI International institutional review board determined that this study was not research involving human subjects.
Similar articles
-
Guaiac-based faecal occult blood tests versus faecal immunochemical tests for colorectal cancer screening in average-risk individuals.Cochrane Database Syst Rev. 2022 Jun 6;6(6):CD009276. doi: 10.1002/14651858.CD009276.pub2. Cochrane Database Syst Rev. 2022. PMID: 35665911 Free PMC article.
-
Prescription of Controlled Substances: Benefits and Risks.2025 Jul 6. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 Jan–. 2025 Jul 6. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 Jan–. PMID: 30726003 Free Books & Documents.
-
Faecal immunochemical tests to triage patients with lower abdominal symptoms for suspected colorectal cancer referrals in primary care: a systematic review and cost-effectiveness analysis.Health Technol Assess. 2017 May;21(33):1-234. doi: 10.3310/hta21330. Health Technol Assess. 2017. PMID: 28643629 Free PMC article.
-
Optimal Stopping Ages for Colorectal Cancer Screening.JAMA Netw Open. 2024 Dec 2;7(12):e2451715. doi: 10.1001/jamanetworkopen.2024.51715. JAMA Netw Open. 2024. PMID: 39699893 Free PMC article.
-
The multitarget fecal immunochemical test versus the fecal immunochemical test for programmatic colorectal cancer screening: a cross-sectional intervention study with paired design.BMC Cancer. 2022 Dec 12;22(1):1299. doi: 10.1186/s12885-022-10372-2. BMC Cancer. 2022. PMID: 36503495 Free PMC article.
References
-
- Kanth P, Inadomi JM. Screening and prevention of colorectal cancer. BMJ 2021;374:n1855. - PubMed
-
- U.S. Preventive Services Task Force. Final Recommendation Statement. Colorectal cancer: screening Rockville, MD: U.S. Preventive Services Task Force; 2021. https://www.uspreventiveservicestaskforce.org/uspstf/recommendation/colo....
-
- Colorectal Cancer Screening. 2024 Alaska Native Health Fact Sheet. 2024. colorectal-cancer-screening-fact-sheet-2024.pdf
Grants and funding
LinkOut - more resources
Full Text Sources